Fig. 5From: Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose studyEffect of MEDI-551 on plasma cell signature in blood. Mean values are plotted. Bars represent standard error of the mean. PC plasma cellsBack to article page